IBRX · ImmunityBio, Inc.

This disclosure represents a HIGH materiality event because it directly concerns regulatory enforcement action by the FDA’s Office of Prescription Drug Promotion (OPDP), which carries potential reputational, commercial, and legal consequences for ImmunityBio’s flagship product ANKTIVA®. The Warning Letter—issued March 13, 2026—focused on promotional statements made in a podcast and a television advertisement, both tied to the company’s marketed therapy. Critically, ImmunityBio clarified that the television ad was never disseminated, mitigating immediate commercial risk, but acknowledged the podcast was published and has since been removed. The company’s corrective actions—including internal process enhancements, executive training, and engagement of external regulatory counsel—signal a material operational pivot toward stricter promotional governance. Management explicitly distinguished between aspirational commentary on the investigational IL-15 platform (e.g., references to 'cancer vaccines' and NCI assessments) and the approved indication for BCG-unresponsive NMIBC, underscoring the importance of message discipline in investor and regulatory communications. Given ANKTIVA®’s status as a first-in-class IL-15 agonist with limited competition in its approved setting, any prolonged regulatory scrutiny or remediation delays could impede commercial execution, payer engagement, or future label expansions. The absence of financial metrics, guidance, or balance sheet disclosures in this filing confirms the event is purely regulatory and operational—not financial—in nature.